Article

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells

2023-04-18

Abstract excerpt

<h4>ABSTRACT</h4> Cyclin dependent kinase 4 and 6 inhibitors (CDK4/6i) such as abemaciclib are routinely used to treat metastatic estrogen receptor positive (ER+)/HER2-negative breast cancer. However, adaptive mechanisms inhibit their effectiveness and allow for disease progression. Using murine metastatic ER+ breast cancer cells, we show that acquired resistance to abemaciclib is accompanied by increase in metas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f23277d9-b71e-5d67-893c-f1400e3ac716
DOI: 10.1101/2023.04.17.537215

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cellsDOI 10.1101/2023.04.17.537215Read

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cellsSemantic proximity Read

Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palbociclib‐hormone therapySemantic proximity Read

Role of Differentially Expressed Proteins in Acquired Resistance to Cdk4/6 Inhibitor in Breast CancerSemantic proximity Read

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast CancerSemantic proximity Read

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read

GPNMB overexpression- a marker of resistance to CDK4/6 inhibitorsSemantic proximity Read

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity Read

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cellsSemantic proximity Read

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody TrastuzumabSemantic proximity Read

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read